Short answer · Medically reviewed summary · Last updated: 2026-05-08
CDKL5 deficiency disorder (CDD) was first described in 2004 as a variant of Rett syndrome, but it has since been reclassified as a distinct neurodevelopmental condition caused by mutations in the CDKL5 gene on the X chromosome. Today, it is recognized as a unique clinical entity characterized by early-onset seizures and severe developmental delay, affecting approximately 1 in 40,000 to 60,000 live births. How was CDKL5 first identified? In 2004, researchers identified mutations in the CDKL5 gene in patients who initially presented with symptoms similar to the early-seizure variant of Rett syndrome.
1 people with CDKL5 have shared their first-person experience on this question at DiseaseMaps.
What is the history of CDKL5?
History of CDKL5: when and how it was discovered, and the milestones in research since, medically reviewed.
CDKL5 deficiency disorder (CDD) was first described in 2004 as a variant of Rett syndrome, but it has since been reclassified as a distinct neurodevelopmental condition caused by mutations in the CDKL5 gene on the X chromosome. Today, it is recognized as a unique clinical entity characterized by early-onset seizures and severe developmental delay, affecting approximately 1 in 40,000 to 60,000 live births.
How was CDKL5 first identified?
In 2004, researchers identified mutations in the CDKL5 gene in patients who initially presented with symptoms similar to the early-seizure variant of Rett syndrome. While it was historically grouped with Rett syndrome, clinicians soon realized that the clinical presentation—particularly the severity of intractable epilepsy—was distinct. This separation was a major milestone, allowing CDKL5 deficiency disorder to be studied as a separate, genetically defined condition.
How has our understanding of CDKL5 evolved?
Modern genetic sequencing has revolutionized the diagnosis of CDKL5. Previously, many patients were misdiagnosed with atypical Rett syndrome or idiopathic epilepsy. Today, the use of chromosomal microarray and targeted gene panels allows for rapid, accurate identification of CDKL5 mutations. The community has grown significantly, with 71 people with CDKL5 currently sharing their lived experiences on DiseaseMaps.org to help map the progression of the condition.
What are the major milestones in treatment and research?
The history of CDKL5 research has shifted from symptom management to targeted therapeutic development. Key milestones include:
- 2004: Discovery of the CDKL5 gene's role in neurodevelopment.
- 2012: The formation of dedicated patient advocacy groups to accelerate research funding.
- 2022: FDA approval of ganaxolone, the first treatment specifically indicated for seizures associated with CDKL5 deficiency disorder.
How has patient advocacy changed the landscape?
The advocacy movement for CDKL5 has been instrumental in shifting the focus toward personalized medicine. By participating in global registries and sharing data, families have helped researchers understand the full spectrum of the disease, moving beyond the "Rett variant" label to a more nuanced, patient-centered understanding of the condition.
Next steps
- Consult a pediatric neurologist or clinical geneticist to discuss the latest genetic testing options.
- Join the CDKL5 community at DiseaseMaps.org to connect with other families and share health data.
- Review current clinical trials via the International CDKL5 Disorder Foundation to stay informed on emerging therapies.
Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): CDKL5 deficiency disorder.
- Orphanet: CDKL5 deficiency disorder (ORPHA:137648).
- Online Mendelian Inheritance in Man (OMIM): #300672.
- International CDKL5 Disorder Foundation: Clinical research resources.
Posted May 23, 2017 by Beth Ann 2120
